Bayer’s s hemophilia A treatment ‘Jivi Inj (damoctocog alfa pegol)’ has come one step near to receiving reimbursement in Korea.

On the other hand, reimbursement discussions for Lilly Korea’s ‘Retevmo (selpercatinib)’ have returned to square one after the company failed to complete pricing negotiations for its RET targeted anticancer drug with the NHIS.

In addition, Teva-Handok started pricing negotiations for its antibody drug for asthma, ‘Cinqair (reslizumab)’ with the NHIS.

According to the industry on the 24th, the NHIS had updated the drug pricing negotiation status of new drugs on its webpage recently.

The drug pricing negotiations for Ji